Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Epidermolysis Bullosa Dystrophica × ON 01910 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 3 Myelodysplastic Syndromes 2 Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Epidermolysis Bullosa Dystrophica 1 Cytopenia 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Anemia, Refractory 1 Adenocarcinoma 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03786237 2026-02-24

Rigosertib for RDEB-SCC

Salzburger Landeskliniken

Phase 1/2 Completed

Carcinoma, Squamous Cell, Epidermolysis Bullosa Dystrophica

Data powered by HemOnc (CC BY 4.0) Colophon ⚡